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Introduction: To assess if an impaired cross-talk between endothelial cells (ECs) and perivascular/multipotent
mesenchymal stem cells (MSCs) might induce a perturbation of vascular repair and leading to a phenotypic switch
of MSC toward myofibroblast in Systemic Sclerosis (SSc).
Methods: We investigated different angiogenic and profibrotic molecules in a tridimentional matrigel assay,
performing co-cultures with endothelial cells (ECs) and bone marrow derived MSCs from patients and healthy
controls (HC). After 48 hours of co-culture, cells were sorted and analyzed for mRNA and protein expression.
Results: ECs-SSc showed a decreased tube formation ability which is not improved by co-cultures with different
MSCs. After sorting, we showed: i. an increased production of vascular endothelial growth factor A (VEGF-A) in
SSc-MSCs when co-cultured with SSc-ECs; ii. an increased level of transforming growth factor beta (TGF-β) and
platelet growth factor BB (PDGF-BB) in SSc-ECs when co-cultured with both HC- and SSc-MSCs; iii. an increase of
TGF-β, PDGF-R, alpha smooth muscle actin (α-SMA) and collagen 1 (Col1) in both HC- and SSc-MSCs when
co-cultured with SSc-ECs.
Conclusion: We showed that during SSc, the ECs-MSCs crosstalk resulted in an altered expression of different
molecules involved in the angiogenic processes, and mainly SSc-ECs seem to modulate the phenotypic switch of
perivascular MSCs toward a myofibroblast population, thus supporting the fibrotic process.Introduction
Systemic slcerosis (SSc) is an autoimmune disease cha-
racterized by early vascular abnormalities and subse-
quent fibroblass activation to myofibroblasts, leading to
fibrosis of the skin and internal organs [1,2]. Much effort
has been made in recent years, to identify the earlier
clinical markers of SSc, to diagnose patients in a very
early phase before the occurrence of fibrosis [3]. Simi-
larly, much effort has been made to identify the earlier
pathogenetic steps that may be able to activate fibro-
blasts after the endothelial injury [4]. Recently, many
studies have pointed out the role of endothelial cells/
pericytes interactions in leading fibrosis after vascular* Correspondence: paola.cipriani@cc.univaq.it
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stated.injury, during different fibrotic disorders [5,6], and these
models open new perspectives to understand the fibrotic
process in SSc. At present, it is well-established that at
the onset of the disease a microvascular injury, associa-
ted to both ischemia/reperfusion damage and impaired
compensatory angiogenesis [7,8], results in a capillary
rarefaction with consequent tissue ischemia. The com-
plex link between vessel disappearance and fibroblast ac-
tivation is still largely unknown. It is well-known that
the maintenance of the existing vasculature and the
stabilization of the newly formed vessel is successfully
achieved by strict interplay between endothelial cells
(ECs) and pericytes, mediated by both direct contact and
orchestrated actions of cytokines and growth factors [9].
During the normal angiogenic process, mesenchymal
pericyte progenitors are recruited in the vascular sprouts
in response to growth factors, mainly PDGF, which isl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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perivascular progenitors is a pivotal step for inducing
ECs to produce active transforming growth factor-β
(TGF-β) [11], which is able to induce maturation of
mural cells [12,13], promoting blood vessel stabilization
and function [14]. Finally, vascular endothelial growth
factor (VEGF), produced by mesenchymal stem cells
(MSCs), makes ECs unresponsive to other proangiogenic
stimuli.
Several studies provide evidence that, during adult life,
resident pericytes, distributed in different tissues, repre-
sent the local sources of stem cells. In fact pericytes may
differentiate toward a variety of mesenchymal populations,
such as osteoblasts, chondrocytes, adipocytes and fibro-
blasts [15], supporting the concept that adult multipotent
MSCs are members of the pericyte family and reside in a
specialized physical location known as the perivascular
niche [16]. In this place, MSCs regulate their own fate by
the heterotypic cell-cell crosstalk with ECs [17]. This
contact maintains MSCs in their quiescent state or,
alternatively, provides signals activating their differentia-
tive process [18]. This phenotypic modulation is a critical
event, which may lead to myofibroblast differentiation,
resulting in abnormal expression of contractile proteins,
such as alpha-smooth muscle actin (α-SMA), and in colla-
gen 1 (Col1) production. The pericyte-myofibroblast tran-
sition seems to be involved in many different diseases. As
shown in experimental models of kidney fibrosis, altered
pericyte-EC crosstalk, after microvascular injury leads to
pericyte detachment, migration, and differentiation toward
myofibroblasts with consequent destabilization and loss of
capillaries [19,20]. Furthermore, in different experimental
models, spinal cord pericytes are identified as the main
progenitor population of scar tissue in the central nervous
system, intestinal pericytes are the main source of myofi-
broblasts, in different models of colitis, and hepatic stellate
cells are the major precursors of myofibroblasts in liver
disease [21-23].
Recently, different authors have shown that bone
marrow-derived MSCs express pericyte markers and
cooperate with ECs to form a vascular network in three-
dimensional cultures, suggesting that these cells may
derive from the bone marrow perivascular sites where
they probably act as pericytes [24,25]. From a transla-
tional point of view, the data obtained in these models
on the role of perivascular cells in the fibrotic process
and their possible involvement in the pathogenesis of
SSc, are intriguing and until now are largely unexplored.
We recently showed that MSCs from SSc patients ex-
press pericyte-specific markers and behave as pericytes.
They display an antiangiogenic and myofibroblast-like
phenotype, with increased production of contractile fiber-
associated proteins, probably due to micro-environmental
cues operating during the disease [26].During SSc, the fibrotic process is strongly mediated
by the effect of several cytokines, including TGF-β and
platelet-derived growth factor (PDGF), and elevated
levels of VEGF have been reported, despite lack of com-
pensative angiogenesis. Of note, it is well-known that
the same molecules are involved in vessel formation and
stabilization. Thus, a perturbation of the normal cross-
talk between ECs and perivascular/MSCs in SSc might
induce an abnormal production of these molecules, in-
ducing vessel instability and perivascular-myofibroblast
phenotypic transition and activation, starting the pa-
thogenic process leading to the classical hallmarks of the
disease: the diffuse fibrosis, on one hand, and the loss of
peripheral vascularization on the other. The aim of the
present study was to assess these specific molecular
pathways during the EC-MSC crosstalk in patients with
early diffuse SSc, in whom the occurrence of fibrosis is
generally earlier and rapidly progressive, when compared
to the limited form. We performed a three-dimensional
angiogenic assay, co-culturing ECs and MSCs from SSc
patients and healthy controls (HCs). After co-culture,
cells were sorted for molecular- and protein-level ana-
lyses. This is the first report in the scientific literature
providing evidence that ECs in SSc may induce a pa-
thogenic phenotype in MSCs, switching from archi-
tectural and metabolic supporting cells to cells with
strong migratory and profibrotic functions, thus poten-
tially modulating vessel instability on one hand, and dif-
ferent pathways involved in the fibrotic process on the
other hand.
Methods
Isolation, culture, immunophenotyping and
differentiation of MSCs
After approval from San Salvatore University Hospital
ethics committee and written informed consent from pa-
tients, MSCs were obtained from 10 SSc patients with
the early diffuse cutaneous form of the disease (disease
duration less than 3 years calculated since the first non-
Raynaud’s symptom of SSc) [27], by aspiration from the
posterior superior iliac crest and cultured and charac-
terized as previously described [28]. Demographic and
clinical characteristics of the patients are shown in
Table 1.
Patients discontinued corticosteroids, oral vasodilators,
intravenous prostanoids or other potentially disease-
modifying drugs, at least one month before biopsies.
None were assumed to be taking immunosuppressants.
Ten frozen bone marrow (BM)-MSCs samples ob-
tained from age-matched healthy women who were bone
marrow donors were used as control. MSCs from both
SSc patients and HCs were plated at a concentration of
2 × 105 cells/cm2 in D-MEM (GIBCO, Carsbald, CA,
USA) supplemented with 10% FBS (Standard South
Table 1 Clinical and demographic features of the 10 patients with early diffuse SSc
Sex/age
(years)














F/46 2010/2 12/2 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2009/3 13/1 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/31 2011/1 13/2 ANA/Scl7-0 Normal/Normal Normal/No Yes/Yes
F/36 2010/2 11/2 ANA/Scl-70 Normal/Normal PAH/No Yes/Yes
M/20 2010/2 11/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/41 2010/2 15/2 ANA/Scl-70 Normal/Normal Normal/No No/No
F/30 2010/2 10/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2010/2 09/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/31 2009/3 14/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/42 2009/3 16/2 ANA/Scl-70 Fibrosis/Normal Normal/No Yes/No
M, male; F, female; MRSS, modified Rodnan skin thickness score (maximum possible score 51); HRCT, high-resolution computed tomography; PFT, pulmonary
function test; ANA, antinuclear antibodies; ACA, anti-centromere antibodies; scl-70, anti-topoisomerase antibodies; PAH, pulmonary arterial hypertension.
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(EuroClone, Milano, Italy) and 100 U Penicillin, 1,000 U
Streptomycin (Biochrom AG, Miramar, Fl, USA). At 80%
confluence the BM-MSCs were split and sub-cultured.
Third-passage (P3) BM-MSCs were analyzed for the sur-
face expression of MSCs antigens (CD45, CD73, CD90,
CD34, CD79a, PDGFRβ) and pericyte markers (α-SMA,
SM22α, NG2, desmin, RGS5) as previously described [24].
Endothelial cell isolation and culture
Microvascular ECs were isolated from skin biopsies from
the same 10 SSc patients and the same 10 bone marrow
donors, who kindly offered a skin sample for research
purposes, after written informed consent. Biopsy samples
(1 × 0.5 cm) of the involved forearm skin (skin score
1/2 at the biopsy site) were washed with PBS (Life
Technologies, Van Allen Way Carlsbad, CA, USA) and four
explants were placed into a 50-mL tube containing 15 mL
of trypsin (Sigma-Aldrich, MO, USA) and then to digest for
45 minutes at 37°C. Cells were cultured in EGM2-MV
(Lonza, Walkersville, MD, USA) at 37°C in a humidified
atmosphere of 5% CO2.
Before the cells reached confluence after approximately
1 week, the heterogeneous pool of cells was exposed to a
CD31-positive selection, performed with the Dynabeads
magnetic CD31 MicroBeads cell sorting system (Invitrogen,
Life Technologies, CA, USA). The beads rapidly target and
partially coat the endothelial cells expressing the CD31
receptor.
After the incubation, the cells were placed in a magnet
(Dynal MPC-S) (Invitrogen, Life Technologies, CA, USA)
for 2 minutes, following the manufacturer’s recommended
protocol for washing and final extraction. The CD31-
negative cells (with no beads attached) were removed du-
ring the successive washings. The positive selected cellswere 99% ECs with a specific phenotype (CD-31, CD-34,
CD-144) (Figure 1a). The cells were used at the third
passages.In vitro angiogenesis assay
Tube formation ability was evaluated using a Matrigel assay
(Matrigel (BD Biosciences, Qume Drive San Jose, CA,
USA) (8.6 mg/mL) was used at 1:1 dilution with EGM2-
MV, without supplement. ECs and MSCs were labeled, be-
fore co-culture in Matrigel, using the green fluorescent dye
PKH67 and red fluorescent dye PKH26 (Sigma, St. Louis,
MO, USA), respectively, according to the manufacturer’s
instructions. ECs and MSCs were seeded alone and in co-
culture ECs/MSCs in a 3:1 ratio. The following co-cultures
were performed: SSc-ECs/SSc-MSCs, SSc-ECs/HC-MSCs,
HC-ECs/HC-MSCs, HC-ECs/SSc-MSCs. After 48 hrs the
total tube length of each well was measured as cells/mm
and photographed. Images were acquired using an
Olympus BX53 fluorescence microscope.Cell sorting of co-cultured cells
After 48 hrs of co-culture, as suggested by available
literature [29,30], tube formation was observed. At
this point, MSCs and ECs were gently removed from
three-dimensional cultures, using Dispase (BD Biosciences
Discovery Labware, Bedford, MA, USA), and mixed with
5 mM ethylenediaminetetraacetic acid (EDTA). Dispase
effectively degrades Matrigel without damaging the em-
bedded cells. Both recovered MSCs and ECs were washed
several times with PBS and re-suspended in 0.1% FBS in
PBS for cell-sorting. The cells were sorted (purity >95%)
by a FACSAria cell sorter (BD Biosciences, Franklin Lakes,
NJ, USA) and further used for gene expression and pro-
tein profiling.
Figure 1 Tubular-like structure formation in Matrigel after 48 hrs. (a) Expression of endothelial cell markers CD31 (PECAM-1), CD34, CD144
by flow cytometric analysis. The histograms in each graph show the increase in fluorescence for each endothelial cell marker (green line)
compared with the expression of an isotype-matched irrelevant monoclonal antibody (mAb) used as control (purple line). (b) Phase contrast
pictures: healthy control (HC)-epithelial cells (ECs) cultured alone form well-organized tube-like structures; systemic sclerosis (SSc)-ECs cultured alone
failed to form well-organized tube-like structures; HC-ECs/HC-mesenchymal stem cells (MSCs) co-culture: the picture shows an increased ability to form
a well-organized tube-like network; SSc-ECs/HC-MSCs co-culture: a decreased capacity of HC-MSCs to improve the tubular formation by SSc-ECs when
cultured alone can be observed; HC-ECs/SSc-MSCs co-culture: the presence of SSc-MSCs did not influence the ability of HC-ECs to form normal tubular
structures, when cultured alone; SSc-ECs/SSc-MSCs co-culture: the impairment to form tubular structures of SSc-ECs was not improved by SSc-MSCs.
The fluorescent images show EC (green) and MSC (red) distribution. Pictures are representative of all experiments. Original magnification 20×. (c) The
tube formation was measured as cells/mm and the performance in each experiment was expressed by the ratio: total tube length in each culture
condition/length in the culture of HC-ECs alone (**P = 0.0002). Results are expressed as median (range) of triplicate experiments.
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Total RNA was extracted from sorted BM-MSCs and ECs
using NucleoSpin RNAXS (Macherey Nagel, Dueren,
Germany) according to manufacturer's instructions and
reverse-transcribed into complementary DNA (cDNA)
with the ThermoScript reverse-transcription PCR system
(Invitrogen, Life Technologies, CA, USA). The qRT-PCR
was performed using SYBR green kits (Applied Bio-
systems, Life Technologies, Van Allen Way Carlsbad, CA,
USA). Results were analyzed after 45 cycles of amplifica-
tion using the ABI 7500 Fast Real Time PCR System.
Primers were designed on the basis of the reported
sequences (Primer bank NCBI; β-actin: 5′-CCTGGCAC
CCAGCACAAT-3′ (forward) and 5′-AGTACTCCGTGT
GGATCGGC-3′ (reverse); α-SMA:5′-CGGTGCTGTCTCTCTATGCC-3′ (forward) and 5′-CGCTCAGTCAGGAT
CTTCA-3′ (reverse); VEGF-A: 5′-AGGGCAGAATCAT
CACGAAGT-3′ (forward) and 5′-GCTGCGCTGATAGA
CATCCA-3′ (reverse); VEGFR2:5′-GTGATCGGAAATG
ACACTGGAG-3′ (forward) and 5′- CATGTTGGTCAC
TAACAGAAGCA-3′ (reverse); Col1A1: 5′-AGGGCCA
AGACGAAGACAGT-3′ (forward) and 5′-AGATCACG
TCATCGCACAACA-3′ (reverse); Col1A2: 5′-TCTGGAT
GGATTGAAGGGACA-3′ (forward) and 5′- CCAACAC
GTCCTCTCTCACC-3′ (reverse); TGF-β: 5′-CTAATGGT
GGAAACCCACAACG-3′ (forward) and 5′- TATCGCCA
GGAATTGTTGCTG-3′ (reverse); PDGF-RR: 5′-TGAGCG
GAAACGGCTCTAC-3′ (forward) and 5′- AGTTCCTCG
GCATCATTAGGG-3′ (reverse); PDGF-BB: 5′-CTCGAT
CCGCTCCTTTGATGA-3′ (forward) and 5′- CGTTGGT
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were normalized to those for β-actin.
Western blot
In order to perform western blot assays, sorted BM-MSCs
and ECs cells were pelleted, washed twice with PBS, lysed
on ice in lysis buffer (1% Triton X-100, 0.5% NP-40,
50mMTris–Cl, pH 7.5, 150 mMNaCl, 1 mM EDTA,
supplemented with 1 mMphenylmethylsulfonyl fluoride, 1
mMNaF, 1 mM Na3VO4, 5 μg/mL aprotinin, 5 μg/mL
leupeptin) for 30 minutes and cleared by centrifugation.
The protein concentration was calculated by Bradford
protein assay reagent (Bio-Rad Laboratories S.r.l., Segrate,
MI, Italy): 50 μg of proteins were separated by SDS-PAGE
and transferred to nitrocellulose membranes. After 1 hr at
room temperature in blocking buffer (5% non- fat milk in
Tris-buffered saline/1% tween 20 (TBS/T)) the membranes
were washed three times for 5 minutes each in TBS/T, and
incubated overnight at 4°C with the primary antibodies:
VEGFR-2 (Invitrogen Corporation, CA, USA), VEGF-A,
PDGF-BB and TGF-β (Abcam, MA, USA), PDGF-R,
Col1A1 and α-SMA (Santa Cruz, Biotechnology, Dallas,
Texas, USA), diluted in 5% bovine serum albumin in TBS/
T. Following three washes with TBS/T, horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz,
Biotechnology) diluted in blocking buffer was added for
30 minutes at room temperature and washed three times
with TBS/T. The detection was performed by enhanced
chemiluminescence detection ECL reaction (Amersham
Pharmacia Biotechnology Piscataway, NJ, USA). All the
signals were quantified by normalizing to the tubulin signal
(CP06 Anti-α-Tubulin Mouse mAb -DM1A). The levels of
proteins, in HC-MSCs cultured alone, were set to 100%;
and all the results were normalized to this value. Immuno-
reactive bands were quantified with densitometry using
ImageJ software (NIH, Bethesda, MD, USA).
Cytofluorimetric analysis
After sorting, HC- and SSc-MSCs were incubated with the
following conjugated monoclonal antibodies: allophyco-
cyanin (APC)-conjugated monoclonal antibodies, including
anti-human CD140b (PDGFRb) (BioLegend, San Diego, CA,
USA) and anti-human CD309 (VEGFR2) (Miltenyi Biotec,
San Diego, CA, USA ). Each fluorescence analysis included
appropriate APC-conjugated negative isotype controls.
Enzyme-linked immunosorbent assay
The concentration of VEGF-A, TGF-β and PDGF-BB re-
leased in single cultures and in co-culture supernatants
were determined by ELISA using Quantikine Human
Immunoassay kits (all by R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s protocol.
After 48 hrs of co-culture and tube formation, media
samples were collected and tested.Statistical analysis
GraphPad Prism 5.0 software was used for statistical
analyses. Results are expressed as median (range). Due to
the non-parametric distribution of our data the Mann-
Whitney U-test was used as appropriate for analyses. Sta-
tistical significance was expressed by a P-value ≤0.05.
Results
SSc-ECs affect the MSCs skill to support tubulogenesis
In our in vitro matrigel assay HC-ECs cultured alone
formed organized tube-like structures. When these cells
were co-cultured with HC- and SSc-MSCs, we observed a
significant improvement in tube-formation ability without
a statistically significant difference. On the contrary, as
shown in Figure 1b-c, using SSc-ECs a significant impair-
ment in tube formation was observed.
Impaired production of angiogenic and fibrotic molecules
in SSc-ECs and SSc-MSCs sorted after 48 hrs of co-culture
VEGF-A/VEGFR2 expression in MSCs
When MSCs were cultured alone, a statistically significant
increase in VEGF-A transcript levels was observed in SSc-
MSCs compared to HC-MSCs (2.11 (1.76 to 3.10) versus
1.11 (0.80 to 1.46), respectively, P <0.0001). As shown in
Figure 2a the presence of SSc-ECs strongly increase the
levels of VEGF-A mRNA transcript in SSc-MSCs when
compared to the other possible mixture of cells (P <0.0001
for all conditions). Basal transcript levels of VEGFR2 were
significantly higher in SSc-MSCs than in HC-MSCs
(1.54 (1.10 to 2.09) versus 1.28 (1.00 to 1.36), respectively,
P <0.0088). The VEGFR2 mRNA levels were significantly
upregulated after co-culture with ECs when compared to
basal conditions (P ≤0.0002 for both). Mirroring what was
observed for the VEGF-A, the expression of VEGFR2 was
strongly increased in SSc-MSCs when co-cultured with
SSc-ECs, as shown in Figure 2b. These results were con-
firmed at the protein level by western blotting analyses
(Figure 2c). As far as the surface expression of VEGFR2 is
concerned, as shown in Figure 2e, we observed a strong
increase in intensity of VEGFR2 in SSc-MSCs when co-
cultured with SSc-ECs.
Furthermore, the VEGF-A protein secreted in each
culture, mirrored the results observed by qPCR and
western blot analysis (Figure 2d).
SSc-ECs increase their expression of TGF-β and PDGF-BB,
after co-culture with MSCs
We investigated the expression of TGF-β in SSc-ECs and
in SSc-MSCs cultured alone and after co-cultures. At the
basal condition, the levels of TGF-β in SSc-ECs were
markedly increased when compared with HC-ECs (3.18
(2.58 to 3.76) versus 1.40 (0.91 to 1.98), respectively,
P <0.0001). When SSc-ECs co-cultured, independent of
the kind of MSCs, the highest levels of TGF-β mRNA
Figure 2 Mesenchymal stem cell (MSC) production of angiogenic molecules when co-cultured with epithelial cells (ECs) from healthy
controls (HCs) and patients with systemic sclerosis (SSc). (a, b) The pictures show the quantification by qRT-PCR of vascular endothelial growth
factor (VEGF)-A (a) and VEGFR-2 (b) mRNA levels in HC- and SSc-MSCs, sorted after co-cultures. Both SSc- and HC-ECs significantly increased VEGF-A
and VEGFR-2 levels in MSCs, compared to the production from MSCs cultured alone (*P = 0.008; **P = 0.0002; ***P <0.0001). (c) Western blot analyses
confirm results observed in qRT-PCR analyses. Pictures are representative of all experiments. (d) VEGF-A ELISA assays. VEGF-A was quantified in the
supernatants of both single culture and co-culture conditions. The results mirrored those observed by qRT-PCR and western blot analysis (**P = 0.0002;
***P <0.0001). All the results are expressed as median (range) of triplicate experiments. (e) The cytofluorimetric analysis shows the fluorescence intensity
of HC- and SSc-MSCs before co-culture (purple histograms) and fluorescence intensity of HC- and SSc-MSCs after co-culture (green histograms).
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results were confirmed at the protein level by western
blotting analyses (Figure 3b).
PDGF-BB was markedly increased in SSc-ECs cultured
alone when compared to HC-ECs (4.28 (2.58 to 4.98)
versus 0.98 (0.87 to 1.57), respectively, P <0.0001]. Mir-
roring the results obtained for TGF-β PDGF-BB levels
were strongly increased in SSC-EC after any kind of co-
culture, as shown in Figure 3c; western blotting analysis
confirmed these data (Figure 3b).
SSc-MSCs increase their expression of TGF-β and PDGF-R
after co-culture with ECs
TGF-β expression at the basal condition was similar in
HC- and SSc-MSCs. As shown in Figure 4a, when SSc-
ECs were added to the culture, we observed the strongest
increase of TGF-β mRNA transcript levels in SSc-MSCs,
when compared to the basal condition and when com-
pared to the other possible mixture of cells (P <0.0001).
No significant difference was observed in PDGF-R
mRNA transcripts levels between HC- and SSc-MSCs at
the basal condition. We observed a significant upregu-
lation after co-culture with ECs when compared to basal
conditions. The expression of PDGF-R was strongly in-
creased in SSc-MSCs when co-cultured with SSc-ECs
(Figure 4b).These results were confirmed at the protein
level by western blotting analyses (Figure 4d). Similarl to
what was observed for VEGFR2, the PDGF-R intensity of
expression was strongly increased in SSc-MSCs when
co-cultured with SSc-ECs (Figure 4c).
The TGF-β and PDGF-BB quantification by ELISA
showed increased release of the growth factors in the
EC/MSC co-culture when compared with ECs and
MSCs cultured alone (Figure 4e, f ).Figure 3 Epithelial cell (EC) production of angiogenic molecules when
controls (HCs) and systemic sclerosis (SSc) patients. (a-c) Expression of
factor (PDGF)-BB in ECs, before and after co-culture with MSCs. SSc-ECs sho
(a) and PDGF-BB (c) compared to the expression levels of HC-ECs, when cu
increase of these expressions was observed, compared to the levels when
were in the co-cultures. All the results are expressed as median (range) of t
analysis of TGF-β and PDGF-R protein in ECs, confirmed those observed atImpaired cross-talk between SSc-ECs and MSCs contribute
to fibrotic switching in SSc-MSCs
Aiming to test whether the co-cultures of SSc-MSCs
with ECs may contribute to SSc-MSC differentiation to-
ward the myofibroblastic phenotype, we examined the
levels of expression of α-SMA, Col1A1, and Col1A2 in
both SSc- and HC-MSCs.
At the basal condition, SSc-MSCs showed a significant
increase in mRNA levels of α-SMA, Col1A1 and Col1A2
when compared with HC-MSCs (α-SMA transcript levels:
SSc-MSCs 2.12 (1.92 to 2.40) versus HC-MSCs 1.09 (0.97
to 1.40), P = 0.0002; Co1A1 transcript levels: SSc-MSCs
2.40 (1.80 to 3.20) versus HC-MSCs 1.15 (0.97 to 1.40),
P = 0.0002; Col1A2 transcript levels: SSc-MSCs 2.55 (2.00
to 2.90) versus HC-MSCs 0.80 (0.60 to 1.20), P = 0.0002).
After co-culture with HC-ECs, the SSc-MSCs displayed
significant downregulation of α-SMA and collagen gene
expression when compared to basal levels (α-SMA,
P = 0.0028; Col1A1, P = 0.0002; Col1A2, P = 0.0002), as
shown in Figure 5a-c. After co-culture with SSc-ECs: 1)
HC-MSCs showed a significant increase of α-SMA and
collagen-related genes when compared to their basal
levels (α-SMA, P = 0.0002; Col1A1, P = 0.0002; Col1A2,
P = 0.0002); 2) SSc-MSCs did not show any difference
in the expression of these genes when compared to
their basal conditions. Finally, the western blot analyses
of α-SMA and Col1A1 mirrored the molecular results
(Figure 5d).
Discussion
This descriptive study is the first report in the available
literature, providing evidence that the pathologic en-
dothelium, via altered MSC-EC crosstalk, impairs the
angiogenic process, and modulate the production ofco-cultured with mesenchymal stem cells (MSCs) from healthy
transforming growth factor-β (TGF-β) and platelet-derived growth
wed a higher amount of mRNA expression levels of both TGF-β
ltured alone. After co-culture with HC- and SSc-MSCs a significant
ECs were cultured alone, the higher levels observed when SSc-ECs
riplicate experiments (**P = 0.0002; ***P <0.0001). (b) Western blot
molecular level Pictures are representative of all experiments.
Figure 4 Mesenchymal stem cells (MSCs) expression of transforming growth factor (TGF)-β and platelet-derived growth factor
(PDGF)-R before and after co-culture with epithelial cells (ECs). (a, b) MSCs from patients with systemic sclerosis (SSc) showed greater mRNA
expression levels of both TGF-β (a) and PDGF-R (b) compared to the expression levels of MSCs from healthy controls (HCs), when cultured alone.
Both SSc- and HC-ECs significantly increased TGF-β and PDGF-R levels in MSCs, compared to the production observed when MSCs were cultured
alone, the higher levels observed in SSc-MSC/SSc-EC co-culture (***P <0.0001). Results are expressed as median (range) of triplicate experiments.
(c) The cytofluorimetric analysis shows the fluorescence intensity of HC- and SSc-MSCs before co-culture (purple histograms) and after co-culture
(green histograms). (d) Western blot analysis of TGF-β and PDGF-R protein in MSCs mirrored the results obtained at molecular level. Pictures are
representative of all experiments. (e, f) TGF-β (e) and PDGF-BB (f) ELISA assays. The protein production, in the supernatant mirrored the results
observed by qRT-PCR and western blot analyses (**P = 0.0002; ***P <0.0001). Results are expressed as median (range) of triplicate experiments.
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MSCs, thus eliciting a phenotypic switch of these multipo-
tent perivascular cells toward a myofibroblastic/profibrotic
phenotype. Our data may support the hypothesis that in
SSc, as shown in other pathological model of fibrosis [31],
previously damaged ECs [32] may be involved in the
earlier steps leading to fibrosis.Using a tri-dimensional Matrigel system for EC/MSC
co-cultures, we showed a highly significant reduction of
the ability to form tubular structures when SSc-ECs
were cultured with SSc-MSCs, whereas the presence of
MSCs (from both patients and HCs) in each condition
improved the angiogenic ability of ECs cultured alone.
To better understand this finding, after 48 hrs of co-
Figure 5 Mesenchymal stem cell (MSC) expression of myofibroblastic molecules before and after co-culture with epithelial cells (ECs).
(a, c) When cultured alone, SSc-MSCs showed higher levels of alpha-smooth muscle actin (α-SMA) (a), collagen (Col)1A1 (b) and Col1A2
(c) compared to MSCs from healthy controls (HCs) cultured alone. Co-cultures with HC-ECs, significantly decreased the mRNA levels of these
genes in HC- and MSCs from patients with systemic sclerosis (SSc). On the contrary, SSc-ECs did not downregulate these gene expressions, when
cultured with both HC- and SSc-MSCs (§P = 0.0028; §§P = 0.0073; **P = 0.0002; ***P <0.0001). Results are expressed as median (range) of triplicate
experiments. (d) Western blot analyses confirmed, at protein level, the results observed by qRT-PCR analyses. Pictures are representative of
all experiments.
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sorting. The analyses of cellular behavior after this inter-
play resulted in dramatic changes in gene expression
and levels of proteins involved in the main steps of the
angiogenic process, including the upregulation of profi-
brotic and extracellular matrix molecules.
In fact, as far as the production of VEGF-A, by MSCs,
was concerned, the highest levels of gene expression and
protein production were observed in SSc-MSCs when co-
cultured with SSc-ECs, although paradoxically the same
co-culture showed the worst tube-formation performance.
To understand this apparent paradox, it must be pointed
out that as already shown [33], perivascular cell-derived
VEGF-A exerts a unique role in driving blood vessel
maturation and stability, functionally distinct from tissue-
derived VEGF-A, the latter promoting the vessel insta-
bility that precedes EC detachment and migration at the
beginning of the angiogenic process. This physiologic
switch, from tissue-derived to mural cell-derived VEGF-A,
occurring at the end of the vessel maturation, fosters
vessel stabilization and ultimately leads to tissue-derived-
VEGF independence [33,34]. Furthermore, Greemberg
et al. [35], demonstrated that VEGF abolished pericyte
coverage of vascular sprouts, leading to vessel des-
tabilization. VEGF-mediated activation of VEGFR2 sup-
pressed PDGFR signaling, through the induction of a
VEGFR/PDGFR complex. These data might explain our
results of lower angiogenic performance, despite theincreased VEGF-A production. Alternatively, a switch
from proangiogenic to antiangiogenic VEGF isoforms
might be considered, as recently described in SSc [36,37],
although available literature shows conflicting results
about the real presence and the potential inhibitory role of
these antiangiogenic isoforms in human tissue [38].
Recent studies proposed an intriguing novel role for
perivascular cells as a potential source of myofibroblasts
in wound healing and in fibrotic disorders. Strong evi-
dence has arisen from studies of the kidney, skin, lung,
liver, and brain [39,40]. SSc, mirroring other fibrotic dis-
eases, is characterized by the abnormal persistence of
myofibroblasts, overexpressing the highly contractile
protein α-SMA and producing collagen and extracellular
matrix components [31]. On the bases of our results, we
may hypothesize that this myofibroblast differentiation
reflects a phenotypic switch of multipotent perivascular
cells in the disease. It has been suggested that these cells
inside the vascular niche, which are considered a natural
reservoir of MSCs/pericyte lineage, are activated to mi-
grate and differentiate toward myofibroblasts, under the
influence of ECs [15,18]. In this context, we described
that SSc-ECs strongly increased the expression of
α-SMA and collagen-related genes, both in SSc- and
HC-MSCs, which were already upregulated in SSc-
MSCs. Of note, HC-ECs were able to downregulate both
α-SMA and collagen genes in SSc-MSCs. Taken toge-
ther, these results show the pivotal role played by
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micro-environment, by factors released during the cross-
talk with pericytes, and point out the pivotal role of
dysfunctional SSc-ECs in influencing MSC differenti-
ation (derived from patients or controls) toward myofi-
broblasts. These in vitro data suggest the hypothesis that
endothelial cell dysfunction, which is a very early event,
in SSc patients, may be a potential trigger leading to
fibrosis, via the involvement of multipotent perivascular
cells.
We showed that SSc-ECs constitutively expressed
higher amounts of PDGF-BB and TGF-β. Furthermore,
when SSc-ECs were co-cultured with SSc-MSCs or
HC-MSCs they induced significantly increased produc-
tion of both these molecules from MSCs. Recently, it
has been shown that the overexpression of PDGF or
TGF-β in normal mouse skin, engineered by adenoviral
vectors, leads to pericyte detachment and vessel desta-
bilization [41]. Furthermore, PDGF and TGF-β induced
accumulation and expansion of connective tissue cells in
the perivascular space, expressing both pericyte and
fibroblast markers. Taken together, these data suggest
that PDGF and TGF-β, produced by ECs play an impor-
tant role in the generation and expansion of myofibro-
blasts, originating from microvascular pericytes [42].
Although PDGF and TGF-β promote vessel stabilization
via pericyte progenitor recruitment and maturation during
vasculogenesis in embryonic life, the same molecules
during adult life might play an opposite role in reactiveFigure 6 Schematic drawing that illustrates the pathogenic conseque
pericytes/mesenchymal stem cells (MSCs) in systemic sclerosis (SSc). I
and platelet-derived growth factor (PDGF)-BB interacting with their specific
differentiation and activation, leading to the fibrotic manifestation of diseas
pericyte proliferation and consequent wall remodeling in arteriolar vessels,
pericyte hyper-production of vascular endothelial growth factor (VEGF)-A m
tissue-derived form of VEGF-A. The increased expression of VEGFR2 on peri
VEGFR2/PDGFR complexes. This pathway abrogates pericyte coverage and
the main pathogenic aspects of the SSc vasculopathy and the impaired coconditions after vascular injuries, thus, leading to vessel
destabilization and myofibroblast generation [43].
The interaction between TGF-β and PDGF-R has been
recently shown as a unique characteristic in scleroderma
fibroblasts, which respond to TGF-β with upregulation
of PDGF-R, making scleroderma fibroblasts more re-
sponsive to the subsequent mitogenic stimulation with
PDGF [44]. In our experiments we observed constitutive
upregulation of TGF-β in SSc-ECs. These cells were able
to induce strong upregulation of PDGF-R on SSc-MSCs,
when co-cultured together. These findings support the
hypothesis that an intramural PDGF/PDGF-R loop, syn-
ergistic with TGF-β production, may cooperate in myofi-
broblast differentiation.
At present, emerging data suggest that MSCs are part
of the perivascular niche, in which heterotypic cell-cell
crosstalk between ECs and MSCs is able to regulate the
perivascular cell fate [15]. This intimate interaction
maintains MSCs in their quiescent state or provides
signals toward differentiation, aiming to repair da-
maged tissues. Using a three-dimensional system for co-
culturing ECs and MSCs, followed by cell sorting, we
demonstrated altered crosstalk between MSCs and ECs
in SSc, resulting in pathogenetically relevant changes in
gene expression and protein levels of several molecules
involved in the angiogenic and profibrotic processes
which are schematically represented in Figure 6. These
alterations lead to a phenotypic switch of perivas-
cular multipotent cells toward migratory and profibroticnces of altered crosstalk between epithelial cells (ECs) and
n SSc, abnormal EC production of transforming growth factor (TGF)-β
receptors, expressed on pericytes/MSCs, may induce myofibroblast
e. Furthermore, the same molecular imbalance leads on one hand to
on the other to pericyte detachment in capillaries. Furthermore,
ay make ECs unresponsive to the proangiogenic stimuli of the
cytes/MSCs may suppress PDGFR signaling through the induction of
leads to vascular instability and regression. These alterations underlie
mpensatory neo-angiogenesis.
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some fibrotic events underling the development and
progression of SSc.
Conclusions
Although our descriptive observational study does not
directly address the mechanism of EC/MSC crosstalk, it
gives us much information on the modulation and pro-
duction of molecules involved in the pathogenesis of SSc,
which may be targeted in future studies and suggests that
a better understanding of the interplay between ECs and
perivascular MSCs might open new future possibilities for
regenerative medicine, targeting the early steps of fibrosis,
for which convincing therapies are not presently available.
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